Anebulo PharmaceuticalsANEB
Market Cap: $56M
About: Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Employees: 2
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.44% more ownership
Funds ownership: 29.72% [Q1] → 30.15% (+0.44%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
3% less capital invested
Capital invested by funds: $22.1M [Q1] → $21.3M (-$770K) [Q2]
13% less funds holding
Funds holding: 15 [Q1] → 13 (-2) [Q2]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for ANEB.